Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4607]

NICE recommends abemaciclib in combination with endocrine therapy for adjuvant treatment of HR+/HER2- early breast cancer

NICE recommends abemaciclib in combination with endocrine therapy for adjuvant treatment of HR+/HER2- early breast...

Mechanical transmission enables EMT cancer cells to drive epithelial cancer cell migration to guide tumour spheroid disaggregation

Mechanical transmission enables EMT cancer cells to drive epithelial cancer cell migration to guide tumour...

Researchers discover genes that predict good response to blood cancer therapy

Researchers discover genes that predict good response to blood cancer therapy

Androgen receptor signaling contributes to targeted therapy resistance in melanoma

Androgen receptor signaling contributes to targeted therapy resistance in melanoma

Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers

Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers

High-intensity focused ultrasound can control prostate cancer with fewer side effects

High-intensity focused ultrasound can control prostate cancer with fewer side effects

New targeted radionuclide alpha therapy improves prostate cancer outcomes

New targeted radionuclide alpha therapy improves prostate cancer outcomes

EHA 2022: Allogeneic CAR T cell therapy shows promising early results for patients with TCL

EHA 2022: Allogeneic CAR T cell therapy shows promising early results for patients with TCL

EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated CLL

EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated...

EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML

EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML

More from ecancer